Open AccessTwo-year outcomes of pro re nata ranibizumab monotherapy for exudative age-related macular degeneration in Japanese patients
Author(s) -
Annabelle A. Okada,
Yamamoto,
Sugitani,
Kunita,
Tosho Rii,
Yokota
Publication year - 2013
Publication title -
clinical ophthalmology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.025
H-Index - 56
eISSN - 1177-5483
pISSN - 1177-5467
DOI - 10.2147/opth.s42189
Subject(s) - medicine , pro re nata , ranibizumab , macular degeneration , ophthalmology , exudative age related macular degeneration , optometry , bevacizumab , chemotherapy
To describe outcomes of intravitreal ranibizumab using a pro re nata regimen for treatment-naive exudative age-related macular degeneration (AMD), in Japanese patients over the first 2 years.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom